Anti-vascular Endothelial Growth Factor Pharmacotherapy in the Treatment of Subretinal Choroidal Neovascularization

Yoreh Barak, MD,1 Mark A Ihnen, MD2 and Shlomit Schaal, MD, PhD3

1. Vitreo-Retinal Fellow; 2. Ophthalmology Resident; 3. Vitreo-Retinal Specialist, Director, Diabetic Retinopathy Service, and Assistant Professor, Department of Ophthalmology and Visual Sciences, University of Louisville, Kentucky, US

Abstract

Vascular endothelial growth factor (VEGF) plays a pivotal role in stimulating the growth of pathologic subretinal choroidal neovascularization (CNV). The increased production of VEGF and subsequent CNV formation can occur in degenerative, inflammatory, and vascular diseases of the retina and choroid, often leading to severe visual impairment. Anti-VEGF agents which are readily available today are much better, more potent, and longer acting in comparison with previous treatment modalities, and therefore have dramatically improved the prognosis of patients with CNV. There are four intravitreal anti-VEGF pharmacotherapies proven by large prospective, multicenter, randomized trials to be effective in the treatment of age-related macular degeneration (AMD)-related CNV: pegaptanib (Macugen®, Eyetech Pharmaceuticals, Palm Beach Gardens, FL), ranibizumab (Lucentis®, Genentech, Inc., South San Francisco, CA), bevacizumab (Avastin®, Genentech, Inc., South San Francisco, CA), and VEGF Trap-Eye (Eylea® Regeneron, Tarrytown, NY). However, there are still many challenges and unanswered questions regarding the optimal anti-VEGF pharmacotherapy agent, the best clinical treatment regimen, the most effective dosage, the optimal injection frequency, and the duration of treatment. The heavy burden of frequent injections on the elderly patient population and physicians begs for a simpler way of drug administration or development of more potent compounds.

Keywords

Vascular endothelial growth factor, subretinal choroidal neovascularization, age-related macular degeneration, pegaptanib, ranibizumab, bevacizumab, VEGF Trap-Eye

Intravitreal anti-vascular endothelial growth factor (VEGF) pharmacotherapy, introduced in 2004,1 has evolved over the last decade to revolutionize the treatment of patients suffering from subretinal choroidal neovascularization (CNV). Anti-VEGF agents, which are readily available today, are much better, more potent, and longer acting in comparison with previous treatment modalities, and therefore have dramatically improved the prognosis of patients with CNV.

Patients losing vision secondary to CNV, such as patients suffering from exudative age-related macular degeneration (AMD), can now expect stabilization and even improvement of their visual acuity, as opposed to the slow and certain visual deterioration that was the rule before the anti-VEGF era.2,4

Vascular Endothelial Growth Factor

VEGF is a diffusible cytokine that promotes angiogenesis and increases vascular permeability. It is a product of a gene family that plays an important role in normal development and angiogenesis.7 The influence of VEGF in retinal diseases is profound. This dimeric glycoprotein of approximately 40 kDa is upregulated in response to hypoxia. It plays a pivotal role in stimulating abnormal growth of pathological new blood vessels in the adult retina and choroid. VEGF is also a potent inducer of vascular permeability and leakage that can lead to retinal edema and thickening.6,8

There is mounting evidence that increased VEGF expression is associated with pathologic CNV.7,9 CNV, a form of abnormal blood vessel growth which emerges from choroidal vessels, penetrates Bruch’s membrane and grows below the retinal pigment epithelium (RPE) space and into the subretinal space.7 Figure 1 shows the different stages of growth of a subretinal choroidal membrane in response to VEGF stimulation.

The increased production of VEGF and subsequent CNV formation can occur in degenerative, inflammatory, neoplastic, traumatic, hereditary, and idiopathic diseases of the retina and choroid. The most commonly encountered conditions associated with CNV are AMD and pathologic myopia. AMD is the leading cause of irreversible vision loss among the elderly population in the Western world.10 All subtypes of exudative AMD, such as retinal angiomatous proliferation, CNV, and polypoidal choroidal vasculopathy, are driven by VEGF, although they differ in anatomical location and clinical behavior7 and respond differently to anti-VEGF...
uveitis and accounts for 2% of severe visual loss. There are favorable uveitic-related CNV which is an established complication of posterior CNV, with 24% of patients in the treatment group experiencing visual loss.

Anti-vascular Endothelial Growth Factor Pharmacotherapies

To date there are four intravitreal anti-VEGF pharmacotherapies proven by large prospective, multicenter, randomized trials to be effective in the treatment of AMD-related CNV. Many smaller trials have demonstrated anti-VEGF pharmacotherapy to be an effective treatment for CNV secondary to other degenerative and inflammatory conditions.

The first intravitreal anti-VEGF pharmacotherapy introduced was an oligoribonucleotide aptamer, pegaptanib (Macugen®, Eyetech Pharmaceuticals, Pfizer, New York, US). Injected every six weeks, it specifically binds and blocks the activity of extracellular VEGF165 isoform. Pegaptanib was shown to have a smaller proportion of patients who lost fewer than 15 letters of visual acuity at 54 weeks compared with sham injection. It is important to note that over 50% of the treated groups lost more than 15 letters and only 33% maintained or gained visual acuity. A meaningful breakthrough was achieved with ranibizumab (Lucentis®, Genentech, Inc., South San Francisco, CA)—a recombinant, humanized, monoclonal antibody antigen-binding fragment (Fab) that neutralizes all active forms of VEGF-A. Monthly intravitreal injections of ranibizumab over the course of 24 months were compared with verteporfin and sham injection in two large studies (Minimally classic/occult trial of the anti-VEGF antibody ranibizumab in the treatment of neovascular AMD [MARINA]) and Anti-vascular endothelial growth factor antibody for the treatment of predominantly classic choroidal neovascularization in age-related macular degeneration [ANCHOR]) and were found to be effective in the treatment of all forms of AMD-related CNV. In both studies, 90% of patients receiving ranibizumab lost fewer than 15 letters and 25–41% gained more than 15 letters, compared with 3.8 and 6% in the sham-injection and verteporfin groups, respectively. Mean increases in visual acuity were 5.4–10.7 letters in the ranibizumab groups, compared with a decrease of 14.9 and 9.8 in the sham-injection and verteporfin studies, respectively. A large number of uncontrolled studies yielded similar positive results for bevacizumab (Avastin®, Genentech, Inc., South San Francisco, CA), the humanized full-size anti-VEGF antibody, demonstrating its therapeutic effect on subretinal CNV after intravitreal injection. These results, in combination with the more affordable cost of bevacizumab, led to widespread off-label use in the treatment of CNV. To date, most intravitreal anti-VEGF injections given in the US involve bevacizumab. The one-year results of the Comparison of age-related macular degeneration treatments trials (CATT), a multicenter, single-blind, non-inferiority trial, provided the final evidence that bevacizumab and ranibizumab have equivalent effects on visual acuity when administered according to the same protocols.
schedule. In the CATT study, patients received intravitreal injections of ranibizumab or bevacizumab on either a monthly schedule or as needed, with monthly evaluation. Bevacizumab administered monthly was equivalent to ranibizumab administered monthly, with 8.0 and 8.5 letters gained, respectively. Bevacizumab administered as needed was equivalent to ranibizumab as needed, with 5.9 and 6.8 letters gained, respectively. VEGF Trap-Eye, the most recent anti-VEGF pharmacotherapy introduced into clinical practice, consists of VEGF receptors 1 and 2 fused to the crystallizable fragment (Fc) portion of a human immunoglobulin G that binds both VEGF-A with high affinity and placental growth factor (PIGF), another molecule involved in pathologic angiogenesis and subsequent CNV formation. Results from two phase III, two-year, identical, randomized, double-masked, non-inferiority trials (VEGF Trap-Eye: investigation of efficacy and safety in wet age-related macular degeneration (VIEW-1 and VIEW-2), designed to compare VEGF Trap-Eye with ranibizumab for the treatment of neovascular AMD, are now available. VEGF Trap-Eye was administered at doses of 0.5 mg or 2.0 mg at four-week dosing intervals or 2.0 mg at eight-week dosing intervals, while ranibizumab was administered at .5 mg every four weeks. The primary endpoint was the proportion of subjects treated with VEGF Trap-Eye who maintained or improved vision at the end of one year, compared with ranibizumab. In VIEW-1 (US), 96, 95, and 95 % of subjects who received VEGF Trap-Eye 0.5 mg monthly, 2 mg monthly, and 2 mg every two months, respectively, achieved maintenance of vision, compared with 94 % of subjects receiving ranibizumab. In VIEW-2 (Europe and Asia) 96 % of subjects in all VEGF Trap-Eye dose groups achieved maintenance of vision, compared with 94 % of subjects receiving ranibizumab. The visual acuity and anatomical outcomes in VIEW-1 and VIEW-2 suggest that VEGF Trap-Eye has the potential to provide outstanding results, similar to those of ranibizumab. VEGF Trap-Eye recently received a unanimous recommendation for approval for the treatment of wet AMD from the Food and Drug Administration (FDA) advisory committee.

**Treatment Regimen**

In the MARINA and ANCHOR studies, which launched the era of widely used intravitreal injections, ranibizumab was administered on a monthly basis. Monthly injections are time-consuming for the patient population and treating physician while placing a significant financial burden on the medical system, with an average cost of $50 and $2,067 per injection of bevacizumab and ranibizumab, respectively. Frequent intravitreal injections also carry a risk of infection, inflammation, and retinal detachment. These important considerations prompted the exploration of newer drug regimens that preserve the therapeutic effect with less frequent injections.

The Phase IIIb, multicenter, randomized, double-masked, sham injection-controlled study of the efficacy and safety of ranibizumab in subjects with subfoveal CNV with or without classic CNV secondary to age-related macular degeneration (PIER) was the first to investigate a less frequent ranibizumab injection schedule. Patients with subfoveal CNV were randomly assigned to receive three monthly injections of ranibizumab followed by quarterly injections on a fixed schedule for one year, for a total of six injections. Patients gained an average of one line of vision at three months, followed by gradual decline over the next nine months. Visual acuity returned to baseline (-0.2 letters) at 12 months. These results led to the conclusion that quarterly injections are inadequate to maintain the visual gain achieved during the first three months of therapy with monthly injections. Subset analysis showed that about 70 % of patients treated with ranibizumab gained an average of 10 letters at three months. Of these, 40 % maintained their visual gain, while 60 % experienced visual decline in the next nine months. Thus there is individual variability in response to ranibizumab injections and it may be possible to tailor treatment based on individual characteristics.

The Prospective OCT study with Lucentis for neovascular AMD (PrONTO) was a small, well-designed, open-label trial initiated to explore the use of optical coherence tomography (OCT) as the basis for a less frequent variable dosing regimen with ranibizumab. Each patient received three initial consecutive monthly injections of ranibizumab (0.5 mg) and was followed up monthly thereafter. Re-treatment with ranibizumab was performed on an as-needed basis depending on OCT or fluorescein imaging and clinical examination. At one year there was a mean 10-letter gain (similar to MARINA and ANCHOR), 5 % less lost fewer than three lines of vision, and 35 % gained three or more lines with a mean of 5.6 injections. The CATT study demonstrated that excellent results for visual acuity could be achieved with less-than-monthly regimens. The mean gain of 5.9 letters with bevacizumab when given as needed, and of 6.8 letters with ranibizumab when given as needed, are the best outcomes observed with less-than-monthly regimens. Ranibizumab given as needed was equivalent to ranibizumab given monthly. Bevacizumab given as needed was equivalent at all time points except at 52 weeks when the comparison was inconclusive. In view of these results, the importance of monthly visits and OCT imaging cannot be overemphasized.

A more individualized approach to treating CNV with anti-VEGF pharmacotherapy which is gaining popularity is ‘treat and extend’. A typical treat-and-extend regimen begins with monthly injections until the signs of subretinal exudation have resolved with confirmation by OCT. The treatment interval is then sequentially lengthened by one to two weeks as long as there are no signs of recurrent exudation. If recurrent exudation is detected on a follow-up visit, the treatment interval is reduced to the previous interval. Treatment is rendered at every visit but...
the time between visits is individualized based on the patient’s response to treatment. This regimen allows maintaining an exudation-free macula with fewer injections. There have been individual favorable reports on applying double-dose anti-VEGF at monthly intervals, or applying a double-dose dosing of a conventional dose at two-week intervals for non-responsive cases and for pigment epithelial detachments. Some patients treated with anti-VEGF pharmacotherapy for CNV experience a massive submacular hemorrhage when the treatment is stopped. One approach that may be helpful in preventing this complication is the treat-and-extend approach with intervals of no longer than three months. We still lack evidence-based recommendations regarding when to stop injecting anti-VEGF pharmacotherapy for the treatment of CNV. In an effort to reduce the number of injections while maintaining the therapeutic effect, combination treatments with PDT, steroids, or radiation have demonstrated some success.

Figure 3 summarizes the four treatment regimens that are currently used in retina practices. It has also been suggested that repetitive injections of intravitreal anti-VEGF pharmacotherapy in patients with AMD result in a decrease in biological response (tachyphylaxis).

Summary and Future Developments

The current delivery method of all anti-VEGF pharmacotherapy in the treatment of CNV is repetitive intravitreal injections. Although VEGF Trap-Eye shows some promise in requiring less frequent injections, many efforts are being made in search of a better, less invasive drug delivery method. Possible future systems may include local delivery as topical drops or long-acting, sustained-release vitreal implants.

Anti-VEGF pharmacotherapy has revolutionized the way we treat CNV. There are several molecular mechanisms that play a role in the development of CNV. Despite the wide variety of anti-VEGF pharmacotherapies available today, there are still many challenges and unanswered questions regarding the determination of the optimal anti-VEGF pharmacotherapy agent, the best treatment regimen, the optimal dosage, the duration of treatment, and the route of administration. Future research and further clinical experience with the use of these agents will shed some light and hopefully clear up some of these unresolved dilemmas.